

| PME panel |                           |  |
|-----------|---------------------------|--|
| versie    | 16-Oct-2018<br>(34 genen) | Centrum voor Medische Genetica Gent  |
| Gene      | OMIM gene ID              | Associated phenotype, OMIM phenotype ID, phenotype mapping key and inheritance pattern   |
| ASAHI     | 613468                    | Farber lipogranulomatosis, 228000 (3), Autosomal recessive; Spinal muscular atrophy with progressive myoclonic epilepsy, 159950 (3), Autosomal recessive   |
| ATP13A2   | 610513                    | Kufor-Rakeb syndrome, 606693 (3), Autosomal recessive; Spastic paraplegia 78, autosomal recessive, 617225 (3), Autosomal recessive   |
| BSCL2     | 606158                    | Encephalopathy, progressive, with or without lipodystrophy, 615924 (3), Autosomal recessive; Lipodystrophy, congenital generalized, type 2, 269700 (3), Autosomal recessive; Neuropathy, distal hereditary motor, type VA, 600794 (3), Autosomal dominant; Silver spastic paraplegia syndrome, 270685 (3), Autosomal dominant  |
| CACNA1A   | 601011                    | Epileptic encephalopathy, early infantile, 42, 617106 (3), Autosomal dominant; Episodic ataxia, type 2, 108500 (3), Autosomal dominant; Migraine, familial hemiplegic, 1, 141500 (3), Autosomal dominant; Migraine, familial hemiplegic, 1, with progressive cerebellar ataxia, 141500 (3), Autosomal dominant; Spinocerebellar ataxia 6, 183086 (3), Autosomal dominant |
| CERS1     | 606919                    | ?Epilepsy, progressive myoclonic, 8, 616230 (3), Autosomal recessive   |
| CLN3      | 607042                    | Ceroid lipofuscinosis, neuronal, 3, 204200 (3), Autosomal recessive  |
| CLN5      | 608102                    | Ceroid lipofuscinosis, neuronal, 5, 256731 (3), Autosomal recessive  |
| CLN6      | 606725                    | Ceroid lipofuscinosis, neuronal, 6, 601780 (3), Autosomal recessive; Ceroid lipofuscinosis, neuronal, Kufs type, adult onset, 204300 (3), Autosomal recessive  |
| CLN8      | 607837                    | Ceroid lipofuscinosis, neuronal, 8, 600143 (3), Autosomal recessive; Ceroid lipofuscinosis, neuronal, 8, Northern epilepsy variant, 610003 (3), Autosomal recessive  |
| CSTB      | 601145                    | Epilepsy, progressive myoclonic 1A (Unverricht and Lundborg), 254800 (3), Autosomal recessive  |
| CTSD      | 116840                    | Ceroid lipofuscinosis, neuronal, 10, 610127 (3), Autosomal recessive   |
| CTSF      | 603539                    | Ceroid lipofuscinosis, neuronal, 13, Kufs type, 615362 (3), Autosomal recessive  |
| DNAJC5    | 611203                    | Ceroid lipofuscinosis, neuronal, 4, Parry type, 162350 (3), Autosomal dominant   |
| EPM2A     | 607566                    | Epilepsy, progressive myoclonic 2A (Lafora), 254780 (3), Autosomal recessive   |

|                 |        |   |
|-----------------|--------|---|
| <i>FARS2</i>    | 611592 | Combined oxidative phosphorylation deficiency 14, 614946 (3),<br>Autosomal recessive; Spastic paraplegia 77, autosomal recessive,<br>617046 (3), Autosomal recessive  |
| <i>GBA</i>      | 606463 | Gaucher disease, perinatal lethal, 608013 (3), Autosomal recessive;<br>Gaucher disease, type I, 230800 (3), Autosomal recessive; Gaucher<br>disease, type II, 230900 (3), Autosomal recessive; Gaucher disease,<br>type III, 231000 (3), Autosomal recessive; Gaucher disease, type IIIC,<br>231005 (3), Autosomal recessive; {Lewy body dementia, susceptibility<br>to}, 127750 (3), Autosomal dominant; {Parkinson disease, late-onset,<br>susceptibility to}, 168600 (3), Isolated cases, Multifactorial |
| <i>GOSR2</i>    | 604027 | Epilepsy, progressive myoclonic 6, 614018 (3), Autosomal recessive  |
| <i>GRN</i>      | 138945 | Aphasia, primary progressive, 607485 (3), Autosomal dominant; Ceroid<br>lipofuscinosis, neuronal, 11, 614706 (3), Autosomal recessive;<br>Frontotemporal lobar degeneration with ubiquitin-positive inclusions,<br>607485 (3), Autosomal dominant   |
| <i>KCNC1</i>    | 176258 | Epilepsy, progressive myoclonic 7, 616187 (3), Autosomal dominant   |
| <i>KCTD7</i>    | 611725 | Epilepsy, progressive myoclonic 3, with or without intracellular<br>inclusions, 611726 (3), Autosomal recessive   |
| <i>KIF5A</i>    | 602821 | {Amyotrophic lateral sclerosis, susceptibility to, 25}, 617921 (3),<br>Autosomal dominant; Myoclonus, intractable, neonatal, 617235 (3),<br>Autosomal dominant; Spastic paraplegia 10, autosomal dominant,<br>604187 (3), Autosomal dominant  |
| <i>LMNB2</i>    | 150341 | ?Epilepsy, progressive myoclonic, 9, 616540 (3), Autosomal recessive;<br>{Lipodystrophy, partial, acquired, susceptibility to}, 608709 (3),<br>Autosomal dominant   |
| <i>MFSD8</i>    | 611124 | Ceroid lipofuscinosis, neuronal, 7, 610951 (3), Autosomal recessive;<br>Macular dystrophy with central cone involvement, 616170 (3),<br>Autosomal recessive   |
| <i>MTFMT</i>    | 611766 | Combined oxidative phosphorylation deficiency 15, 614947 (3),<br>Autosomal recessive  |
| <i>NEU1</i>     | 608272 | Sialidosis, type I, 256550 (3), Autosomal recessive; Sialidosis, type II,<br>256550 (3), Autosomal recessive  |
| <i>NHLRC1</i>   | 608072 | Epilepsy, progressive myoclonic 2B (Lafora), 254780 (3), Autosomal<br>recessive   |
| <i>PPT1</i>     | 600722 | Ceroid lipofuscinosis, neuronal, 1, 256730 (3), Autosomal recessive   |
| <i>PRICKLE1</i> | 608500 | Epilepsy, progressive myoclonic 1B, 612437 (3), Autosomal recessive   |
| <i>PRNP</i>     | 176640 | Cerebral amyloid angiopathy, PRNP-related, 137440 (3), Autosomal<br>dominant; Creutzfeldt-Jakob disease, 123400 (3), Autosomal<br>dominant; Gerstmann-Straussler disease, 137440 (3), Autosomal<br>dominant; Huntington disease-like 1, 603218 (3), Autosomal<br>dominant; Insomnia, fatal familial, 600072 (3), Autosomal dominant;<br>{Kuru, susceptibility to}, 245300 (3); Prion disease with protracted<br>course, 606688 (3), Autosomal dominant  |
| <i>SACS</i>     | 604490 | Spastic ataxia, Charlevoix-Saguenay type, 270550 (3), Autosomal<br>recessive  |

|                 |        |  |
|-----------------|--------|--|
| <i>SCARB2</i>   | 602257 | Epilepsy, progressive myoclonic 4, with or without renal failure, 254900 (3), Autosomal recessive  |
| <i>SERPINI1</i> | 602445 | Encephalopathy, familial, with neuroserpin inclusion bodies, 604218 (3), Autosomal dominant  |
| <i>TBC1D24</i>  | 613577 | DOORS syndrome, 220500 (3), Autosomal recessive; Deafness , autosomal recessive 86, 614617 (3), Autosomal recessive; Deafness, autosomal dominant 65, 616044 (3), Autosomal dominant; Epileptic encephalopathy, early infantile, 16, 615338 (3), Autosomal recessive; Myoclonic epilepsy, infantile, familial, 605021 (3), Autosomal recessive |
| <i>TPP1</i>     | 607998 | Ceroid lipofuscinosis, neuronal, 2, 204500 (3), Autosomal recessive; Spinocerebellar ataxia, autosomal recessive 7, 609270 (3), Autosomal recessive  |

Gene symbols used are according to the HGNC guidelines. For some genes a previously HGNC-approved symbol is in brackets.

Each Phenotype is followed by its MIM number, phenotype mapping key and inheritance pattern.

OMIM release used for OMIM disease identifiers and descriptions: July 04, 2018

#### Possible phenotype mapping keys

- (1) the disorder is placed on the map based on its association with a gene, but the underlying defect is not known
- (2) the disorder has been placed on the map by linkage; no mutation has been found
- (3) the molecular basis for the disorder is known; a mutation has been found in the gene
- (4) a contiguous gene deletion or duplication syndrome, multiple genes are deleted or duplicated causing the phenotype

Brackets, "[ ]", indicate "nondiseases," mainly genetic variations that lead to apparently abnormal laboratory test values (e.g., dysalbuminemic euthyroidal hyperthyroxinemia).

Braces, "{ }", indicate mutations that contribute to susceptibility to multifactorial disorders (e.g., diabetes, asthma) or to susceptibility to infection (e.g., malaria).

A question mark, "?", before the phenotype name indicates that the relationship between the phenotype and gene is provisional. More details about this relationship are provided in the comment field of the map and in the gene and phenotype OMIM entries.